This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 2191
tella, Inc. researches and develops regenerative and cell medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de tella, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2.00 |
| 52 Week High | JP¥227.00 |
| 52 Week Low | JP¥2.00 |
| Beta | 1.85 |
| 1 Month Change | -97.96% |
| 3 Month Change | -97.47% |
| 1 Year Change | -98.99% |
| 3 Year Change | -98.97% |
| 5 Year Change | -99.64% |
| Change since IPO | -99.33% |
Noticias y actualizaciones recientes
Rentabilidad de los accionistas
| 2191 | JP Life Sciences | Mercado JP | |
|---|---|---|---|
| 7D | -75.0% | 1.3% | 1.4% |
| 1Y | -99.0% | -34.2% | 28.4% |
Rentabilidad vs. Industria: 2191 underperformed the JP Life Sciences industry which returned 13.5% over the past year.
Rentabilidad vs. Mercado: 2191 underperformed the JP Market which returned 0.6% over the past year.
Volatilidad de los precios
| 2191 volatility | |
|---|---|
| 2191 Average Weekly Movement | 33.1% |
| Life Sciences Industry Average Movement | 6.5% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Precio estable de las acciones: 2191's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 2191's weekly volatility has increased from 19% to 33% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2004 | 30 | Yuichiro Yazaki | www.tella.jp |
Resumen de fundamentos de tella, Inc.
| Estadísticas fundamentales de 2191 | |
|---|---|
| Capitalización bursátil | JP¥50.65m |
| Beneficios(TTM) | -JP¥898.00m |
| Ingresos (TTM) | JP¥89.00m |
0.6x
Ratio precio-ventas (PS)-0.1x
Ratio precio-beneficio (PE)¿Está 2191 sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 2191 | |
|---|---|
| Ingresos | JP¥89.00m |
| Coste de los ingresos | JP¥193.00m |
| Beneficio bruto | -JP¥104.00m |
| Otros gastos | JP¥794.00m |
| Beneficios | -JP¥898.00m |
Últimos beneficios comunicados
Mar 31, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -35.46 |
| Margen bruto | -116.85% |
| Margen de beneficio neto | -1,008.99% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado 2191 a largo plazo?
Ver rendimiento histórico y comparativa